REC-1245 Shows No DLTs, 43% REC-4881 Polyp Reduction; $390M Burn Guidance
Recursion reported Q1 milestones across multiple wholly owned programs, including well-tolerated REC-1245 with no dose-limiting toxicities in 16 patients and REC-4881 Phase 2 showing a median 43% polyp reduction at Week 13. The company reiterated 2026 operational cash burn guidance of under $390 million, extending runway into early 2028.
1. 2026 Cash Burn Guidance Extends Runway
Recursion reiterated full-year 2026 operational cash burn guidance of under $390 million, supporting a cash runway into early 2028 without the need for additional financing.
2. REC-1245 Safety and Pharmacokinetics
Preliminary Phase 1/2 data for REC-1245 (RBM39 degrader) in 16 solid tumor patients show no dose-limiting toxicities to date, predictable dose-dependent pharmacokinetics and mostly Grade 1-2 treatment-related adverse events; dose escalation is ongoing to determine the recommended Phase 2 dose.
3. REC-4881 Phase 2 Efficacy Signals in FAP
REC-4881 (MEK1/2 inhibitor) achieved a median 43% reduction in polyp burden at Week 13 and 53% at Week 25 following a treatment break, with 40% of patients improving Spigelman stage; safety was consistent with MEK inhibition and FDA engagement to define a registrational pathway has been initiated, with an update expected in 2H 2026.
4. REC-4539 Phase 1 Trial Initiation
The first patient has been dosed in the Phase 1 ENLYGHT trial of REC-4539, an AI-designed LSD1 inhibitor with a reversible mechanism and CNS penetration profile, delivered in approximately 20 months to address platelet toxicity and advance differentiated epigenetic targeting in solid tumors and AML.